Overview

First- Line Treatment With Durvalumab Plus XELOX Chemotherapy in Advanced Gastrointestinal Neuroendocrine Carcinoma

Status:
Recruiting

Trial end date:
2026-12-31

Target enrollment:

Participant gender:

Summary

First-Line Treatment With Durvalumab Plus XELOX Chemotherapy in Advanced Gastrointestinal Neuroendocrine Carcinoma - a prospective Single-arm Phase II Study [NCT ID not yet assigned]

Phase:

Phase 2

Details

Lead Sponsor:

Peking Union Medical College Hospital

Treatments:

Capecitabine
Durvalumab
Oxaliplatin